<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00854932</url>
  </required_header>
  <id_info>
    <org_study_id>NeoPInS</org_study_id>
    <nct_id>NCT00854932</nct_id>
  </id_info>
  <brief_title>Neonatal Procalcitonin Intervention Study</brief_title>
  <acronym>NeoPInS</acronym>
  <official_title>Effect of Procalcitonin-guided Decision Making on Duration of Antibiotic Therapy in Suspected Neonatal Early-onset Sepsis: Multicenter Prospective Randomized Intervention Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luzerner Kantonsspital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kantonsspital Winterthur KSW</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Triemli Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kantonsspital Graubuenden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jeroen Bosch Ziekenhuis, s'-Hertogenbosch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Reinier de Graaf Gasthuis Delft</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thomayerova Teaching Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Flevo Ziekenhuis, Almere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Atrium Medisch Centrum, Heerlen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ijssalland Ziekenhuis, Capelle aan den Ijssel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sint Franciscus Gasthuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vlietland Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Joseph's Healthcare Hamilton</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Luzerner Kantonsspital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In neonates, clinical signs and symptoms associated with early-onset sepsis are non-specific
      and currently available tests have poor positive and negative predictive values. The
      investigators hypothesize that procalcitonin (PCT) has a reliable negative predictive values
      to allow a reduction in duration of empiric antibiotic therapy in suspected neonatal
      early-onset sepsis with unchanged outcome. This study is designed as a multi-center,
      prospective, randomized intervention trial. The duration of antibiotic therapy in the
      standard group is based on the attending physician's assessment of the probability of
      infection during hospitalisation. In the PCT group, if infection is considered to be unlikely
      or possible, antibiotic therapy is discontinued when two consecutive PCT values are within
      the normal range.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed description according our pilot study (see reference). This trial is designed to
      exclude a difference in rate of re-infection or death greater than 2%. Assuming a 2%
      reinfection/death rate in each group, 770 patients are required for a power of 80% at
      alpha=0.05. To allow for some unevaluable cases 800 per group will be included. Based on the
      data of the pilot study (see reference), with a number of 770 per group a difference between
      mean antibiotic therapy durations of 10 hours can be detected at two-sided alpha of 0.05 with
      a power of 95%.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The absolute reduction of the duration of antibiotic therapy with unchanged outcome</measure>
    <time_frame>1 month</time_frame>
    <description>Unchanged outcome = proportion of infants with a recurrence of infection requiering additional courses of antibiotic therapy within 72 hours after ending antibiotic therapy and/or death in the first month of life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalisation</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>PCT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PCT values are within the normal range.Antibiotic therapy can be continued despite fulfilled criteria at the discretion of the attending physician. These divesions from the stopping rules will be reported for further analysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The duration of antibiotic treatment in the standard group is based on the attending physician's assessment of the risk of classification: infection unlikely for 36-72 hours, infection possible for 5-7 days, infection probable of proven for 7-21 days depending on clinical course, laboratory values and positive cultures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Procalcitonin-guided decision making</intervention_name>
    <description>In the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PDT values are within the normal range.</description>
    <arm_group_label>PCT group</arm_group_label>
    <other_name>Procalcitonin-guided duration of antibiotic therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Term and near term infants with a gestational age &gt; 34 weeks

          -  Suspected sepsis in the first 3 days of life requiring empiric antibiotic therapy

          -  Parental consent

        Exclusion Criteria:

          -  Surgery in the first week of life

          -  Severe congenital malformations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Stocker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kantonsspital Luzern, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>children's Hospital of Lucerne</name>
      <address>
        <city>Lucerne</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Stocker M, Fontana M, El Helou S, Wegscheider K, Berger TM. Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis: prospective randomized intervention trial. Neonatology. 2010;97(2):165-74. doi: 10.1159/000241296. Epub 2009 Sep 24.</citation>
    <PMID>19776651</PMID>
  </reference>
  <reference>
    <citation>Stocker M, Hop WC, van Rossum AM. Neonatal Procalcitonin Intervention Study (NeoPInS): Effect of Procalcitonin-guided decision making on duration of antibiotic therapy in suspected neonatal early-onset sepsis: A multi-centre randomized superiority and non-inferiority Intervention Study. BMC Pediatr. 2010 Dec 8;10:89. doi: 10.1186/1471-2431-10-89.</citation>
    <PMID>21143869</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2009</study_first_submitted>
  <study_first_submitted_qc>March 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2009</study_first_posted>
  <last_update_submitted>March 4, 2016</last_update_submitted>
  <last_update_submitted_qc>March 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Luzerner Kantonsspital</investigator_affiliation>
    <investigator_full_name>Stocker Martin</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>procalcitonin</keyword>
  <keyword>sepsis</keyword>
  <keyword>newborn</keyword>
  <keyword>intervention study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

